Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01248351 | Reversibility of Dual Antiplatelet Therapy by Platelets | PHASE2 | COMPLETED | 6 | — | — | Nov 1, 2010 | Mar 1, 2011 | Apr 28, 2011 | 1 | Austria |
pharmacodynamic measurements of platelet function will be assessed at baseline, after 3 days administration of aspirin and clopidogrel (300 mg loading with aspirin and clopidogrel, maintenance with 100 mg aspirin and 75 mg clopidogrel, respectively) after retransfusion of stored platelets and 24 hours thereafter
| Arm | Type | Description |
|---|---|---|
| autologous stored platelets | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| autologous stored platelets | OTHER | Administration of autologous stored platelets |
| administration of autologous stored platelets | OTHER | administration of autologous stored platelets |
Inclusion Criteria: 1. Informed consent 2. Healthy volunteers, male or female (after exclusion of pregnancy if they are on birth control pill or have a contraceptive coil implanted) 3. Age of consent 4. Weight: 70 kg - 100 kg 5. Platelet count 240 000 to 440 000/µL 6. Hematocrit \> 40% 7. readiness...